(Q39580861)

English

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

scientific article published on March 4, 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

breast neoplasm

1 reference

based on heuristic

inferred from title

antineoplastic resistance

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21377448

26 November 2024

author name string

Koichi Azuma

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Junji Tsurutani

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kazuko Sakai

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hiroyasu Kaneda

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yasuhito Fujisaka

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Masayuki Takeda

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Masahiro Watatani

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Tokuzo Arao

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Taroh Satoh

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Isamu Okamoto

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Takayasu Kurata

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kazuto Nishio

12

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kazuhiko Nakagawa

13

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

4 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0006291X11003639?httpAccept=text/xml

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

https://api.elsevier.com/content/article/PII:S0006291X11003639?httpAccept=text/plain

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Biochemical and Biophysical Research Communications

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

407

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

219-224

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

2

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients

3

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

4

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

5

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

6

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

7

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

8

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Fibroblast growth factor signalling: from development to cancer

9

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer

10

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Drug-sensitive FGFR2 mutations in endometrial carcinoma

11

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease

12

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

13

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

14

1 reference

10.1016/J.BBRC.2011.03.002

https://api.crossref.org/works/10.1016/J.BBRC.2011.03.002

26 November 2024

Identifiers

10.1016/J.BBRC.2011.03.002

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39580861&oldid=2279957879"